Reviva Pharmaceuticals is set to present positive data regarding speech latency improvements with brilaroxazine in schizophrenia patients from the Phase 3 RECOVER trial. The findings will be shared at the CNS Summit 2024, held in Boston, Massachusetts, from November 10-13.
The poster presentation, titled "Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine," will be presented by Dr. Jan Sedway of WCG Clinical on Tuesday, November 12th, from 5:00 - 7:00 PM ET. The presentation will highlight how selecting patients based on speech latency can improve the observed treatment effects of brilaroxazine.
Brilaroxazine and Schizophrenia Treatment
Brilaroxazine (RP5063) is Reviva's investigational drug for schizophrenia and other CNS disorders. Schizophrenia is a chronic brain disorder affecting approximately 1% of the world's population. Patients often experience a range of symptoms, including speech deficits, which can significantly impact their social and occupational functioning. Current treatments often fall short in addressing these cognitive and communicative aspects of the illness, creating an unmet medical need.
The RECOVER trial is a Phase 3 study designed to evaluate the efficacy and safety of brilaroxazine in patients with schizophrenia. The positive speech latency data suggests a potential benefit of brilaroxazine in improving this critical aspect of the condition. Further details about the study design, patient population, and specific results will be available during the poster presentation at the CNS Summit 2024.
Reviva's Pipeline
Reviva Pharmaceuticals is a biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases. Their pipeline includes brilaroxazine and RP1208, both new chemical entities discovered in-house. Reviva holds composition of matter patents for both compounds in the United States, Europe, and other countries.
